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Aim
Pre B-cell colony-enhancing factor (PBEF) is intricately
involved in inflammation and fibrosis, functional poly-
morphisms of PBEF have been previously shown to
influence PBEF expression and pulmonary damage. Sys-
temic sclerosis (SSc) is a disease in which inflammation,
fibrosis and pulmonary deterioration are prominent hall-
marks. Therefore we here investigate the role of the
PBEF -1001T>G and PBEF -1543C>T polymorphisms in
the genetic predisposition to systemic sclerosis (SSc)
susceptibility and pulmonary involvement.
Patients and methods
We genotyped DNA from 2737 SSc patients and 1913
matched healthy controls, both from 8 different ethnic
populations. Genotyping was performed using custom
Taqman 5´allelic discrimination assays. In addition,
PBEF serum expression levels were measured by ELISA
and correlated with genotypes.
Results
In two separate populations and in a meta-analysis, the
combined PBEF -1543CC -1001TT genotype, hence
carrying no minor alleles, was found associated with
SSc susceptibility (P=0.009 OR 1.20 (95% CI 1.05-
1.37). In addition, these subjects showed an increased
decline in forced vital capacity (FVC) over 15 years fol-
low-up (P=0.02) (HR 1.64, 95%CI: 1.02-2.64) and a
higher PBEF serum concentration (P<0.01), compared
to carriers of minor alleles. On the other hand,
patients with genotype PBEF -1001TT were at lower
risk for PAH development within 15 years of disease
onset compared to the carriers with genotypes PBEF-
1001GG and PBEF-1001TG (P<0.001) (HR 3.29, 95%
CI: 1.52-7.12).
Conclusions
Our data identify PBEF as a novel candidate gene that
influences SSc susceptibility, pulmonary function and
the development of PAH.
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